A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue - NLG-T-01

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000389-35-DK

Enrollment

120

Registered

2006-05-16

Start date

2006-05-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed non-cutaneous peripheral T-cell lymphoma

Interventions

Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Cyclophosphamide Concentration unit: mg/m2 milligram(s)/square meter Concentration number: 750-6000 Product Name: vincristin Pharmaceuti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of all stages Following histologic subtypes( WHO classification are eligible for inclusion in the study: Peripheral T-Cell lymphoma, Angioimmunoblastic T-Cell lymphoma, NK/T nasal type t_cell lymphoma, Enteropaty type T-cell lymphoma, Primary systemic alk-negative anaplastic large cell lymphoma( T-or null phenotype) Age 18-60 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Primary cutanous T-or null-cell anaplastic large cell lymphoma alk positive, primary systemic T-or null cell anaplastic large cell lymphoma Whp performance status grade 4 Patients with severe cardiac, pulmonary, neurologic,psychiatric, renal, hepatic or metabolic disease. Pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026